-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Retro-2
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1201652-50-7.gif)
| Category | Filovirus |
| CAS | 1201652-50-7 |
| Description | Retro-2 is a selective inhibitor of retrograde protein trafficking at the endosome-trans-Golgi network interface. Retro-2 is an ebolavirus (EBOV) infection inhibitor with an EC50 of 12.2 µM in HeLa cells. Retro-2 induces cell Autophagy. |
Product Information
| Synonyms | retro-2|1429192-00-6|Retro-2 cycl|2-(5-methylthiophen-2-yl)-3-phenyl-1,2-dihydroquinazolin-4-one|2,3-Dihydro-2-(5-methyl-2-thienyl)-3-phenyl-4(1H)-quinazolinone|RN 1-001|CHEMBL2322644|SCHEMBL15558640|EX-A2664|Retro-2, >=98% (HPLC)|AKOS037643482|NCGC00370733-05|NCGC00370733-07|AS-16580|HY-114698|AM20210028|CS-0064117|D81087|A900656|4(1H)-Quinazolinone,2,3-dihydro-2-(5-methyl-2-thienyl)-3-phenyl-|2-(5-Methylthiophen-2-yl)-3-phenyl-2,3-dihydroquinazolin-4(1H)-one|(+/-)-2-(5-methylthiophen-2-yl)-3-phenyl-2,3-dihydroquinazolin-4(1h)-one |
| Molecular Weight | 320.41 |
| Molecular Formula | C19H16N2OS |
| Canonical SMILES | CC1=CC=C(S1)C2NC3=CC=CC=C3C(=O)N2C4=CC=CC=C4 |
| Boiling Point | 461.9±40.0 °C at 760 mmHg |
| Flash Point | 233.2±27.3 °C |
| Purity | ≥98% (HPLC) |
| Density | 1.2±0.1 g/cm3 |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | White to yellow (Solid) |
| Storage | 4°C, protect from light * In solvent : -80°C, 6 months -20°C, 1 month (protect from light) |
| Complexity | 437 |
| Exact Mass | 320.09833431 |
| Index Of Refraction | 1.629 |
| In Vitro | Retro-2 (1 μM; 1-4 hours) induces Autophagy in GFP-LC3-expressing HeLa cells and promoted the dramatic cytoplasmic accumulation of large autophagosomes. Retro-2 (1 μM; 0.5-4 hours) treatment hows an increase over time of the abundance of LC3-II protein in cells. Retro-2 impairs the trafficking between autophagosomes and lysosomes. Retro-2 abolishes autolysosomes formation. Retro-2 (20 μM; pretreatment for 30 min) inhibits HeLa cell intoxication by ricin, Shiga-like toxins 1 (Stx1) and 2 (Stx2). Retro-2 blocked invasion of cells by the intracellular parasite Leishmania, as well as replication of non-enveloped viruses, including polyoma-, papilloma-, and adeno-associated viruses. |
| In Vivo | Retro-2 (2-200 mg/kg; i.p; daily; for 21 days) treatment clearly protects from lethal nasal exposure to ricin in mice. 200 mg/kg of Retro-2 fully protects mice against ricin challeng |
| Target | EC50: 12.2 µM (Ebolavirus) |
| Vapor Pressure | 0.0±1.1 mmHg at 25°C |
| XLogP3-AA | 4.4 |
